Evidence map›Paper›PMID 35844445›Full record

ArticleComputational and mathematical methods in medicine2022

A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma.

Yixin Zheng, Jie Xu, Jiexiang Lin, Yuan Lin

RetractedAbstract readRetracted Publication
In one paragraph

Article in Computational and mathematical methods in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Identification of TNFRSF1A as a potential biomarker for osteosarcoma.Cancer biomarkers : section A of Disease markers · 2024
    Article
  5. Article
  6. Article
  7. Retracted: A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma.Computational and mathematical methods in medicine · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Yixin ZhengDepartment of Orthopaedics, Fujian Provincial Hospital, Fuzhou 350001, China.ORCID https://orcid.org/0000-0003-2583-6632
Jie XuDepartment of Orthopaedics, Fujian Provincial Hospital, Fuzhou 350001, China.ORCID https://orcid.org/0000-0002-9921-8792
Jiexiang LinShengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, China.ORCID https://orcid.org/0000-0002-7212-7583
Yuan LinDepartment of Orthopaedics, Fujian Provincial Hospital, Fuzhou 350001, China.ORCID https://orcid.org/0000-0002-3326-7006

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Backgrounds: Osteosarcoma (OS) is easy to metastasis. Necroptosis-related long noncoding RNA (lncRNA) (NRlncRNA) plays a vital role in the tumorigenesis of many malignant tumors. Nonetheless, there have been few studies investigating the relations between NRlncRNA and OS. During the investigation, NRlncRNAs in OS were confirmed and characterized and their relationships with prognoses were investigated. Methods: NRlncRNAs were downloaded from The Cancer Genome Atlas (TCGA) OS expression data and clinical-pathological information. First, univariate Cox regression and LASSO regression analyses were used to screen for prognostic-related NRlncRNAs. Second, multivariate regression analyses were used to establish a prognostic nomogram for predicting individual survival probability. Survival analyses demonstrated that high-risk patients (HRPs) had a poor prognosis. In addition, gene set enrichment analyses (GSEA) were used to identify gene function in high- and low-risk groups based on the survival mode. Results: The 7 NRlncRNAs (AC004812.2, AC022915.1, AC073073.2, AC090559.1, AL512330.1, DDN-AS1, and SENCR) were shown to have a distinct difference and were used to construct an NRlncRNA signature. Using the signature as a risk score was an independent factor for OS patients. The signature divided OS patients into the high- and low-risk groups. Furthermore, the seven lncRNAs were significantly enriched in cell migration and metabolism. Conclusions: The 7 NRlncRNA survival models have the potential to serve as therapeutic targets and molecular biomarkers for patients with OS, as well as to precisely predict OS prognoses.

Indexed as

Bone NeoplasmsOsteosarcomaRNA, Long NoncodingBiomarkers, TumorGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateNecroptosisPrognosisBiomarkers, TumorRNA, Long Noncoding

Identifiers

PMID35844445
PMCPMC9283071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.